NCT07798505PHASE1RecruitingAccepts Healthy Volunteers
A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
Hemab ApS
Start Date
8/17/2026
Completion Date
4/30/2027
Summary
The purposes of this clinical study are 1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.
Eligibility Criteria
Age Range: 18 years to 50 years
Inclusion Criteria:
* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.
Exclusion Criteria:
* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \<6 weeks postpartum.
* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.
Interventions
DRUG
HMB-003
DRUG
Placebo
Conditions
Healthy Adult Participants
Locations
Worldwide Clinical Trials
San Antonio, Texas 78217
United States